939792-89-9

Basic information

• Product Name: (S)-1-(benzofuran-2-yl)ethanamine
• Synonyms: (S)-1-(benzofuran-2-yl)ethanamine;(alphaS)-alpha-Methyl-2-benzofuranmethanamine;2-BenzofuranMethanaMine, a-Methyl-, (aS)-
• CAS NO: 939792-89-9
• Molecular Formula: C10H11NO
• Molecular Weight: 161.2
• Mol File: 939792-89-9.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.122
• CAS DataBase Reference: (S)-1-(benzofuran-2-yl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(benzofuran-2-yl)ethanamine(939792-89-9)
• EPA Substance Registry System: (S)-1-(benzofuran-2-yl)ethanamine(939792-89-9)

Safety Data

• Hazardous Substances Data: 939792-89-9(Hazardous Substances Data)

Usage

General Description

(S)-1-(benzofuran-2-yl)ethanamine is a chemical compound with the molecular formula C10H11NO. It is classified as an amine, specifically a secondary amine, and is commonly used in the field of organic chemistry. (S)-1-(benzofuran-2-yl)ethanamine consists of a benzofuran ring, which is a heterocyclic compound containing a fused benzene and furan ring, attached to an ethylamine group. It is used in research and pharmaceutical applications, and its structure allows it to interact with biological systems in various ways, making it a valuable tool for studying biochemical processes and drug development. Additionally, (S)-1-(benzofuran-2-yl)ethanamine has potential therapeutic uses due to its interactions with various receptors and enzymes in the body. Overall, this chemical compound has important implications in the fields of chemistry, biochemistry, and medicine.

Upstream product

• 1646-26-0 1-(benzo[b]furan-2-yl)ethanone 
• 77287-34-4 formamide 
• 119619-37-3 1-(benzofuran-2-yl)ethan-1-ol 
• 91880-85-2 1-(benzofuran-2-yl)ethan-1-one oxime 
• 99059-83-3 1-(benzofuran-2-yl)ethanamine 
• 108-21-4 Isopropyl acetate 
• 638-11-9 isopropyl butyrate 
• 141-78-6 ethyl acetate 
• 1240636-16-1 C₁₄H₁₇NO₂ 
• 1392234-16-0 C₁₄H₁₇NO₂ 
• 533-58-4 2-Iodophenol 

Downstream Products

• 1212877-42-3 (R)-1-(benzofuran-2-yl)ethylamine 
• 1392234-16-0 C₁₄H₁₇NO₂ 

Relevant articles and documents

Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors

Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is Pseudomonas aeruginosa, which persists within the lungs of CF sufferers despite intensive antibiotic treatment. P. aeruginosa elastase (also known as LasB or pseudolysin) is a key virulence determinant that contributes to the pathogenesis and persistence of P. aeruginosa infections in CF patients. The crucial role of LasB in pseudomonal virulence makes it a good target for the development of an adjuvant drug for CF treatment. Herein we discuss the discovery of a new series of LasB inhibitors by virtual screening and computer assisted drug design (CADD) and their optimization leading to compounds 29 and 39 (Ki = 0.16 μM and 0.12 μM, respectively).

CATALYST COMPOUNDS

The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.

CATALYST COMPOUNDS

The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.